New Jersey Assembly Bill A1526

New Jersey 2026-2027 Regular Session

• Introduced: 1/13/26
• Refer: 1/13/26
• Failed: 1/13/26
• Passed: 1/13/26

Caption

Establishes Psilocybin Behavioral Health Access and Therapy Pilot Program; appropriates $6 million.

Impact

If enacted, this bill will significantly influence state health laws by introducing a new model for the therapeutic use of psilocybin in clinical settings. By allowing hospitals to participate in clinical trials and access federal funding, the bill aims to build a comprehensive system for the safe delivery of psilocybin therapy. Additionally, it will facilitate the collection of data on patient outcomes which can guide future legislative efforts related to psychedelic treatments in New Jersey.

Summary

Assembly Bill A1526 proposes the establishment of a Psilocybin Behavioral Health Access and Therapy Pilot Program in New Jersey, allocating $6 million to study the efficacy of psilocybin for treating various behavioral health conditions. The bill aims to create a framework for hospitals to conduct research in compliance with FDA guidelines and to evaluate psilocybin as a viable treatment option. With a rising number of adults dealing with behavioral health disorders, the legislature acknowledges the potential of psilocybin as a treatment approved by the FDA for certain conditions, including treatment-resistant depression.

Contention

Notable discussions surrounding Bill A1526 may include debates over the appropriateness of using psilocybin in healthcare and concerns regarding the risks associated with psychedelic substances. As many states explore similar legislative pathways, questions about safety, accessibility, and the potential societal impact of psychedelic therapy will likely emerge. The bill's provisions for oversight, data collection, and compliance with federal regulations will be critical in addressing public concerns and ensuring the program's legitimacy.